It appears Davita may be looking at expanding their expertise and offerings by looking at purchasing hemodiafiltration devices. Some say NXTM may be in its sights. I personally believe AEMD is on their radar.
They are closest to the testing results of the Hemopurifier, as they are the ones doing it.
The should look at Aethlon Medical's (AEMD) Hemopurifier.
Time Magazine said it was one of the 10 best inventions.
Davita is currently testing this device for FDA approval for HIV, HCV, Ebola, etc.
Whenever it drops, there appears to be a strong underlying bid that yanks the price right back up.
I could see it closing higher today.
If what you say is true, the after a split there will only be 7 million shares outstanding and a float of only 4 million shares.
That's unheard of .
There are only 36 million shares outstanding with a float of only 21 million.
No way they're doing a reverse split.
Also, is that why volume has tripled today form an average of 70m to over 215m? With a corresponding surge in price from 1.17 to 1.34 ????
Something good is coming your way.
Reading about Bob Simon's death on a car crash today, they said he was preparing a story on Ebola and the search for a cure for this Sundays broadcast. He was working on it with his daughter, Tanya Simon, a producer. Chance that Aethlon could be mentioned.
Remember, all responses to paid bashers is money in their pocket.
Do not respond.
In case anyone forgot about the results due out soon from Boston University’s CTE Center, working in conjunction with Aethlon Medical’s Exosome Sciences subsidiary, I think we may be in for some major breakthroughs in diagnosing this disease at a stage other than postmortem. It’s obviously too late for Mosi Tatupu but this could mean changing the trajectory of life for untold numbers of people around the world, particularly those who play contact sports. This is a big deal for Aethlon, one that I think will continue to establish what a gem this little company is.
Additionally, and perhaps even more importantly, AEMD launched their long awaited FDA approved study yesterday, utilizing their Hemopurifier to treat patients with Hepatitus C who have end stage renal disease. This is an enormous deal and there is one thing that should not be missed here. While the company mentions further on efficacy studies it also states:
“our current feasibility study also contributes safety data, which is the sole human challenge to advance Hemopurifier® therapy against category “A” threats whose virulence does not allow for human efficacy studies to be conducted.”
This means that it is quite likely that after this study, should it be as successful as has been documented in other countries, Aethlon’s Hemopurifier should be approved to treat all category “A” threats. You must read the full article available on the Chairman’s blog, an online publication which is a vehicle for Chairmen and CEO’s to let industry colleagues and a host of other interested parties know what they are doing. In Jim Joyce’s address, category “A” threats (such as Ebola) are detailed. They are numerous and deadly. While the stock may have hit a bit of a lull lately it is pretty clear that the important science is advancing rapidly. Stay tuned.
AEMD: Launch of FDA Study & CTE Results Expected Soon
In case anyone forgot about the results due out soon from Boston University's CTE Center, working in conjunction with Aethlon Medical's Exosome Sciences subsidiary, I think we may be in for some major breakthroughs in diagnosing this disease at a stage other than postmortem. It's obviously too late for Mosi Tatupu but this could mean changing […]
Read more of this post
I would guess the author of the article.
I believe SA is out of Israel, if I'm not mistaken.
I could be wrong, but those are my assumptions.